This study is testing how effective a new vaccine is in preventing respiratory infections caused by the respiratory syncytial virus (RSV).

Respiratory syncytial virus (RSV) is a common seasonal virus that infects the airways of the lungs. Some people, especially older adults or those living with some long-term conditions, can experience serious complications, including inflammation of the lungs of pneumonia.

This international study is being carried out in Greater Manchester by a team of researchers at Manchester University NHS Foundation Trust.


  • aged 65+
  • no serious illness that is not under control with medication
  • no history of anaphylaxis or allergic reactions to vaccines


Manchester Royal Infirmary
(part of Manchester University NHS Foundation Trust)


Taking part will involve:

  • Attending at least four clinic visits and two telephone calls over a 19-month period.
  • Clinic visits will include a range of tests (eg blood samples, heart and blood pressure checks) as well as questions about lifestyle and medical history
  • Completing a weekly diary of any respiratory symptoms.
  • Receiving a new vaccine*

* Participants will be randomly selected to receive either the new vaccine or a placebo.

Recruiting until

  • 14/02/2022

Want to take part or learn more?